携带BRAF V600E突变的严重皮肤朗格汉斯细胞组织细胞增多症患者对维莫非尼有显著反应。 - Suppr

Suppr

超能文献

Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation.

作者信息

Charles Julie, Beani Jean-Claude, Fiandrino Giacomo, Busser Benoit

机构信息

Dermatology Unit, Univ. Grenoble Alpes, IAB, CHU de Grenoble, F-38000 Grenoble, France.

出版信息

J Am Acad Dermatol. 2014 Sep;71(3):e97-9. doi: 10.1016/j.jaad.2014.03.038.

DOI:10.1016/j.jaad.2014.03.038

PMID:25128147

Abstract

摘要

相似文献

Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation.携带BRAF V600E突变的严重皮肤朗格汉斯细胞组织细胞增多症患者对维莫非尼有显著反应。

J Am Acad Dermatol. 2014 Sep;71(3):e97-9. doi: 10.1016/j.jaad.2014.03.038.

Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis.维莫非尼作为BRAF突变型朗格汉斯细胞组织细胞增多症的一线治疗药物。

J Am Acad Dermatol. 2015 Jul;73(1):e29-30. doi: 10.1016/j.jaad.2014.10.045.

Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.携带 BRAF V600E 突变的多系统和难治性 Erdheim-Chester 病和朗格汉斯细胞组织细胞增生症中维莫非尼的显著疗效。

Blood. 2013 Feb 28;121(9):1495-500. doi: 10.1182/blood-2012-07-446286. Epub 2012 Dec 20.

Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis.维莫非尼在一名患有高危朗格汉斯细胞组织细胞增多症的婴儿中的应用。

JAMA Oncol. 2015 Sep;1(6):836-8. doi: 10.1001/jamaoncol.2015.0736.

Access to molecular guided therapy for Langerhans cell histiocytosis patients.朗格汉斯细胞组织细胞增多症患者获得分子导向治疗的机会。

J Am Acad Dermatol. 2015 Jul;73(1):e31. doi: 10.1016/j.jaad.2015.03.007.

Saving orphans: BRAF targeting of histiocytosis.拯救孤儿：BRAF 靶向治疗组织细胞增生症。

Blood. 2013 Feb 28;121(9):1487-8. doi: 10.1182/blood-2013-01-475962.

Circulating cell-free BRAF as a biomarker in children with Langerhans cell histiocytosis.循环无细胞 BRAF 作为朗格汉斯细胞组织细胞增生症患儿的生物标志物。

Br J Haematol. 2017 Aug;178(3):457-467. doi: 10.1111/bjh.14695. Epub 2017 Apr 25.

Multisystemic and Multiresistant Langerhans Cell Histiocytosis: A Case Treated With BRAF Inhibitor.多系统多耐药性朗格汉斯细胞组织细胞增生症：应用 BRAF 抑制剂治疗 1 例

J Natl Compr Canc Netw. 2015 Jun;13(6):715-8. doi: 10.6004/jnccn.2015.0086.

Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.维莫非尼在携带 BRAF V600E 突变的儿童朗格汉斯细胞组织细胞增生症中提供了快速而显著的临床应答，但使用游离循环细胞 DNA 的 ddPCR 并不能消除低水平的微小残留病灶。

Int J Hematol. 2021 Dec;114(6):725-734. doi: 10.1007/s12185-021-03205-8. Epub 2021 Aug 12.

Langerhans cell histiocytosis associated with chronic myelomonocytic leukaemia both harbouring the same BRAF V600E mutation: efficacy of vemurafenib.朗格汉斯细胞组织细胞增多症与慢性粒单核细胞白血病均伴有相同的BRAF V600E突变：维莫非尼的疗效

J Eur Acad Dermatol Venereol. 2021 Feb;35(2):e120-e121. doi: 10.1111/jdv.16850. Epub 2020 Sep 1.

引用本文的文献

Expression and Clinical Correlation of PD-1/PD-L1 and VE1(BRAFp.V600E) in Pediatric Langerhans Cell Histiocytosis.PD-1/PD-L1和VE1（BRAFp.V600E）在儿童朗格汉斯细胞组织细胞增多症中的表达及临床相关性

Mediterr J Hematol Infect Dis. 2023 May 1;15(1):e2023035. doi: 10.4084/MJHID.2023.035. eCollection 2023.

Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis.朗格汉斯细胞组织细胞增生症中的信号通路、微环境和靶向治疗。

Cell Commun Signal. 2022 Dec 19;20(1):195. doi: 10.1186/s12964-022-00917-0.

International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults.国际专家共识建议：成人朗格汉斯细胞组织细胞增生症的诊断与治疗。

Blood. 2022 Apr 28;139(17):2601-2621. doi: 10.1182/blood.2021014343.

Case Report: Early Association of Vemurafenib to Standard Chemotherapy in Multisystem Langerhans Cell Histiocytosis in a Newborn: Taking a Chance for a Better Outcome?病例报告：新生儿多系统朗格汉斯细胞组织细胞增生症中维莫非尼与标准化疗的早期联合应用：能否借此获得更好的治疗结果？

Front Oncol. 2021 Dec 13;11:794498. doi: 10.3389/fonc.2021.794498. eCollection 2021.

Frequency detection of BRAF V600E mutation in a cohort of pediatric langerhans cell histiocytosis patients by next-generation sequencing.采用下一代测序技术检测儿科朗格汉斯细胞组织细胞增生症患者中 BRAF V600E 突变的频率。

Orphanet J Rare Dis. 2021 Jun 11;16(1):272. doi: 10.1186/s13023-021-01912-3.

Efficacy of BRAF-Inhibitor Therapy in BRAF -Mutated Adult Langerhans Cell Histiocytosis.BRAF抑制剂疗法对BRAF突变型成人朗格汉斯细胞组织细胞增多症的疗效

Oncologist. 2020 Dec;25(12):1001-1004. doi: 10.1002/onco.13541. Epub 2020 Oct 12.

Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.系统性组织细胞增多症（朗格汉斯细胞组织细胞增多症、 Erdheim-Chester 病、Destombes-Rosai-Dorfman 病）：从致癌突变到炎症性疾病。

Curr Oncol Rep. 2019 May 21;21(7):62. doi: 10.1007/s11912-019-0810-6.

Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature.维莫非尼治疗朗格汉斯细胞组织细胞增多症：1例儿科患者报告及文献复习

Oncotarget. 2018 Apr 24;9(31):22236-22240. doi: 10.18632/oncotarget.25277.

Cutaneous Langerhans cell histiocytosis with gastrointestinal involvement treated with dabrafenib.用达拉非尼治疗的伴有胃肠道受累的皮肤朗格汉斯细胞组织细胞增多症。

JAAD Case Rep. 2017 Dec 20;4(1):95-97. doi: 10.1016/j.jdcr.2017.07.028. eCollection 2018 Jan.

Insights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapies.朗格汉斯细胞组织细胞增多症发病机制的见解：靶向治疗的发展

Immunotargets Ther. 2016 Oct 12;5:81-91. doi: 10.2147/ITT.S91058. eCollection 2016.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验